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Aims Significant brady- and tachyarrhythmias may occur in active endurance athletes. It is controversial whether these
arrhythmias do persist after cessation of competitive endurance training.
Methods
and results
Among all 134 former Swiss professional cyclists [hereafter, former athletes (FAs)] participating at least once in the
professional bicycle race Tour de Suisse in 1955–1975, 62 (46%) were recruited for the study. The control group
consisted of 62 male golfers matched for age, weight, hypertension, and cardiac medication. All participants were
screened with history, clinical and echocardiographic examination, ECG, and 24 h ECG. The time for the last
bicycle race of FAs was 38+6 years. The mean age at examination was 66+ 6 years in controls and
66+7 years in FAs (P ¼ 0.47). The percentage of study participants with .4 h current cardiovascular training
per week was identical. QRS duration (102+20 vs. 95+ 13 ms, P ¼ 0.03) and corrected QTc interval (416+ 27
vs. 404+ 18, P ¼ 0.004) were longer in FAs. There was no significant difference in the number of isolated atrial
or ventricular premature complexes, or supraventricular tachycardias in the 24 h ECG; however, ventricular
tachycardias tended to occur more often in FAs than in controls (15 vs. 3%, P ¼ 0.05). The average heart rate
was lower in FAs (66+9 vs. 70+ 8 b.p.m.) (P ¼ 0.004). Paroxysmal or persistent atrial fibrillation or flutter
was reported more often in FAs (P ¼ 0.028). Sinus node disease (SND), defined as bradycardia of ,40 b.p.m.
(10 vs. 2%), atrial flutter (6 vs. 0%), pacemaker for bradyarrhythmias (3 vs. 0%), and/or maximal RR interval of
.2.5 s (6 vs. 0%), was more common in FA (16%) than in controls (2%, P ¼ 0.006). Observed survival of all FAs
was not different from the expected.
Conclusions Among FAs, SND occurred significantly more often compared with age-matched controls, and there is trend towards
more frequent ventricular tachycardias. Further studies have to evaluate prevention of arrhythmias with extreme
endurance training, the necessity of regular follow-up of heart rhythm, and management of arrhythmias in former
competitive endurance athletes.
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Introduction
The effect of chronic high-intensity endurance exercise may result
in cardiac changes called ‘athlete’s heart’, including typical morpho-
logical changes and a slow heart rate with significant brady- and
tachyarrhythmias.1 –7 In active athletes, first degree and second
degree atrioventricular (AV) block type, Wenckebach, are not of
concern; however, Mobitz type II second degree AV block or com-
plete heart block are rarely seen.8,9
It has been debated whether changes in cardiac structure and
function persist in elderly endurance athletes, and whether there
is a higher prevalence of arrhythmic complications or the need
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for pacemaker therapy. Some studies found an increased frequency
of supraventricular and ventricular premature complexes during
and after exercise in middle aged to elderly athletes.10,11 Also, a
higher prevalence of ventricular arrhythmias and sinus bradycardia
in elderly male athletes with a lifelong history of regular physical
exercise12 or ‘lone’ atrial fibrillation in vigorously exercising
middle-aged men have been reported.9,13 A 12 year follow-up
study of 20 veteran athletes reported on two former endurance
athletes with atrial fibrillation combined with complete heart
block and 15 s asystole necessitating pacemaker implantation.14
Profound bradyarrhythmias in elderly athletes because of sinus
node disease (SND) may increase the risk of sudden cardiac
death.9 Implantation of a permanent pacemaker has been reported
in up to 11% of former marathon runners in a small study.14 So far,
however, there is no large study on the problem of arrhythmias or
SND nor is there any case-matched control study on arrhythmias
in athletes in the long-term follow-up.
The aim of our study was to evaluate ECG changes, arrhythmias,
and signs of SND in the long-term follow-up 30–50 years after
year-long high endurance training in former professional cyclists
(FAs) by comparing them to case-matched controls who had
never performed any high-endurance competition.
Methods
Study subjects
The study groups consisted of 62 male FAs, aged 66+ 6 years and
62 male controls, aged 66+7 years, who never performed professional
endurance training. All cyclists had to have at least participated once in
the professional cycling race Tour-de-Suisse during the years 1955
until 1975. Among these 134 cyclists, 24 have died (cause of death
unknown in seven, cancer in four, car accident in three, leukaemia in
two, suicide in two, chronic hepatitis/liver failure in two, coronary
artery disease in two, cerebral haemorrhage in one, and alcohol
abuse in one). The median age at death was 62+ 12 years (median,
67 years; range, 39–79 years) in 21 of 24 deceased FAs. Seven
persons were living abroad, 12 could not be traced, and 29 did not
want to participate in the study. Thus, 62 (46%) agreed to participate
in the study. The controls were selected among 309 male senior
leisure time golfers consisting of all senior golfers from the database
of two regional golf clubs, who never performed in high-endurance
training. All golfers were contacted with a letter where they had to
fill in data regarding whether they wanted to participate, their age,
height, weight, and other details including information on current
and previous physical exercise. Among the 165 men who agreed to
participate, 62 were frequency matched for age, body mass index,
hypertension, and the current hours of physical training. Smoking
was more common in controls and could not be matched. Previous
smoking was significantly more common in golfers (P, 0.0001),
there was no significant difference in the occurrence of hyperlipidemia
(P ¼ 0.32), diabetes (P ¼ 1.0), or positive family history for coronary
artery disease (P ¼ 0.24).
The cyclists were competitors for 11+ 4 years and stopped their
professional time with participating in competition 38+ 7 years ago
(median, 38 years; range, 15–49 years). During their professional
time, they cycled an estimate of 25 200+9700 km/year (median,
25 000; range, 9000–40 000) maximally. One bicycle year was defined
as riding 1000 km on the bicycle per year. FAs reported an estimate
of 225+140 (median, 196 years; range, 60–730 years) bike years in
their professional time and 119+ 116 bike years (median, 100 years;
range, 0–625 years) after they stopped competition. Overall, the FAs
had achieved 342+ 181 bike years (median, 311 years; range, 60–975
years), compared with 12+ 21 bike years (median, 3 years; range,
0–120 years) in the control group (P, 0.0001).
All hours of sport-related energy expenditure were counted per
week including swimming, jogging, playing tennis, rowing, or riding
the bicycle. We divided the hours of walking or playing golf (without
carts) by four to make energy expenditure and cardiovascular effect
comparable with cycling or running. The current hours were 4.6+
4.4 (median, 4 h; range, 0–20 h) in FAs vs. 3.3+1.7 h in controls
(median, 3 h; range, 1–8 h) (P ¼ 0.03). There was no significant diffe-
rence in persons with more than 4 h of sport-related cardiovascular
training per week: 52% of FAs vs. 44% of controls (P ¼ 0.47).
However, at the time of this study, the FAs were cycling more than
controls with 3882+4170 km per year (median, 2500 years; range,
0–17 000 years) compared with 348+862 km per year (median, 0;
range, 0–4500) in controls (P, 0.0001). Contrarily, controls were sig-
nificantly more often jogging and rowing. In addition to the electrocar-
diographic and echocardiographic examinations, a detailed patient
history using a questionnaire and an interview were obtained.
The study was approved by the local ethics committee and informed
consent was obtained from all study participants.
A total of 44 (71%) FAs admitted the use of any performance enhan-
cing agents including amphetamines in 20 of 44 (45%), stenamine
(another amphetamine) in seven (16%), coramine in five (11%), and
anabolic steroids in four (9%). Other performance enhancing agents
used occasionally included wine and ephedrine.
Electrocardiogram at rest
and Holter electrocardiogram
A 12-lead resting electrocardiogram (EGC) was recorded for each par-
ticipant. For the ambulatory Holter ECG, digital three-channel ECG
recorder was used (Lifecard CF from DelmarReynolds, UK). The
exploring electrodes were placed on the middle of the sternum and
on the fifth rib at the left and the right anterior axillary line. The
recording quality was checked for stability and the capability to
detect P-waves. Participants were instructed to undertake a usual
strenuous physical activity and to keep a diary for the registration
period. Holter recordings were analysed with commercial software
(Pathfinder V 8.602 from DelmarReynolds, UK). All findings of the
ECG and Holter ECG were reviewed by U.B.
Definitions
Supraventricular tachycardias and ventricular tachycardias were
defined as a sudden increase of three or more following beats at a
rate of .120 b.p.m.
The frequency of atrial premature complexes (APCs) or ventri-
cular premature complexes (VPCs) was defined as: none, ,1 h21;
rare, 1 and ,248/24 h; occasional, 248 and ,1439/24 h; fre-
quent, 1440/24 h.
Definition of sinus node disease
The presence of SND was determined in 116 subjects without
b-blockers (eight with b-blocker therapy excluded). SND was
defined by the presence of more than one of the following criteria:
an average heart rate ,50 b.p.m. at day-time or ,40 b.p.m. at night
and/or maximal RR interval of at least 2.5 s, atrial flutter, or pacemaker
implantation for SND.15
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Echocardiography
A complete two-dimensional and Doppler echocardiographic examin-
ation was performed in all subjects according to the recommendations
of the American Society of Echocardiography,16 including two-
dimensionally guided M-mode measurements using 512 Acuson
Sequoia machines and Aplio 80 Toshiba. Echocardiography was per-
formed on the same day as the resting ECG and the commencement
of the Holter ECG recording. Left ventricular muscle mass index was
calculated using the Devereux-modified American Society of Echocar-
diography cube equation.17 Data of left ventricular ejection fraction
and left ventricular muscle mass index were used for this study. All
studies were digitally stored and sent to C.A.J. for subsequent
review, if necessary.
Statistics
Descriptive statistics include frequencies and percentages for categori-
cal data, mean+ SD for approximately normally distributed data and
additionally median [range] for markedly non-normally distributed
data. Fisher’s exact test and x2 test were used to compare the categ-
orical data between FAs and controls. The Mann–Whitney test was
used to compare the continuous data. Correlations between continu-
ous variables were analysed using Spearman’s rank correlation. A
P-value of ,0.05 was considered to be statistically significant. All
reported P-values are two-sided and have not been adjusted for mul-
tiple testing. Data were analysed using SPSS 11 (SPSS inc., Chicago, IL,
USA). Survival of 119 former participants of the Tour de Suisse was
compared with the expected survival curve of a male age- and calendar
time-matched Swiss reference population.
Results
Patient characteristics and symptoms
Clinical details of both groups are shown in Table 1. There was no
significant difference between the two groups in age, body mass
index, and cardiovascular risk factors—apart from a history of
smoking. Dizziness was the only cardiac symptom more common
in FAs (P ¼ 0.02).
There was no significant difference between the two groups
regarding the occurrence of syncope. A history of previous pace-
maker implantation was present in two FAs for symptomatic
SND with bradycardic atrial flutter.
Functional class was similar and most commonly limited because
of obesity, hypertensive heart disease, and obstructive lung disease
as a result of smoking.
The intake of cardiac medication did not differ significantly
between both groups. A total of 45 FAs (73%) and 47 (76%) con-
trols did not take any of these drugs.
Electrocardiographic data
Resting ECG findings are shown in Table 2. The resting ECG
showed a slightly lower heart rate in FA than in controls, as well
as a longer QRS duration and corrected QT interval. There was
no significant difference in right or left bundle branch block, left
anterior or posterior hemiblock or atrioventricular block.
However, chronic or paroxysmal atrial fibrillation or flutter
occurred significantly more common in FA (P ¼ 0.0028).
In the Holter ECG (see Table 3), FAs had a significantly lower
average heart rate (P ¼ 0.004). The minimal heart rate in the
24 h ECG tended to be lower in FAs (P ¼ 0.05). Bradycardia
with heart rates ,50 b.p.m. during the day occurred significantly
more often in FAs than in controls (P ¼ 0.004). Two FAs had
also sinus bradycardia ,40 b.p.m. during the day. Bradycardic epi-
sodes were asymptomatic in all FAs.
Four athletes (6%) vs. 0% of the controls had a maximal RR
interval exceeding 2.5 s (P ¼ 0.12). The maximal RR interval was
significantly longer in the cyclists than in controls (P ¼ 0.008).
One FA had an asymptomatic sinus pause of 5.3 s; overall, he
had 192 pauses .2.5 s.
Sinus node disease as defined above was more common in FAs
than in controls (P ¼ 0.004). There was no significant difference in
the group of FAs with or without SND regarding age, number of
bicycle years, or current hours of endurance training. However,
the length of previous competitive years was slightly longer,
13+6 years in FAs with signs of SND vs. 10+3 years in those
without (P ¼ 0.06).
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Table 1 Clinical findings of the 62 former professional
cyclists and 62 controls
FAs
(n5 62)
Controls
(n 5 62)
P-value
Age, years 66+7 66+6 0.47
Body mass index, kg/m2 25.6+2.8 25.9+2.4 0.58
Hypertension, n(%) 22 (35) 18 (29) 0.56
Current medication
Beta blocker, n(%) 5 (8) 3 (5) 0.72
ACEI/ARB, n(%) 11 (18) 10 (16) 1.0
Calcium-channel
blocker,n(%)
3 (5) 2 (3) 1.0
Diuretic, n(%) 7 (11) 4 (6) 0.53
Angina pectoris 3 (5) 1 (2) 0.62
Dyspnea on exertion
NYHA class I, n(%) 53 (86) 55 (89) 0.80
NYHA class II, n(%) 7 (11) 6 (10)
NYHA class III/IV, n(%) 2 (3) 1 (2)
Syncope, ever, n(%) 7 (11) 2 (3) 0.44
Dizziness, n(%) 17 (27) 6 (10) 0.02
Palpitations, n(%) 8 (13) 8 (13) 1.0
Pacemaker, n(%) 2 (3) 0 0.50
Heart failure ever, n(%) 2 (3) 0 0.50
Myocardial infarction, n(%) 3 (5) 1 (2) 0.62
Atrial flutter or fibrillation,
n(%)
6 (10) 0 0.028
Atrial flutter, persistent 3
Atrial flutter, paroxysmal 1
Atrial fibrillation,
persistent
2
Atrial fibrillation,
paroxysmal
0
FAs, former athletes; BSA, body surface area; NYHA, New York Heart
Association; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin
receptor blocker.
Sinus node disease and arrhythmias in former professional cyclists 73
In FAs with atrial fibrillation or flutter, the total number of
bicycle years was 504+ 283 (median, 485; range, 243–975) vs.
327+ 166 (median 290, range 60–720; P ¼ 0.04) in those
without.
Frequent and/or
complex supraventricular
or ventricular arrhythmias
There was no significant difference in the occurrence of atrial pre-
mature complexes or supraventricular tachycardias between the
groups (see Table 4).
There was no significant difference in the percentage of subjects
with VPCs or the number of VPCs between the groups (see
Table 5). However, polymorphic ventricular premature complexes
and VPC as bigemini and trigemini were more common in controls.
Ventricular tachycardias tended to occur more often in FAs than in
controls (P ¼ 0.05). The length of VT ranged from three to 14 in
FAs and three to eight in controls. The number of runs of VT
ranged from one to 326 in FAs and from one to eight in controls.
Echocardiographic data
In FAs, the echocardiographic examination showed that the left
ventricular ejection fraction was slightly lower than in controls
(62+ 8 vs. 64+6%, P ¼ 0.049). There was no significant diffe-
rence in the thickness of the interventricular septum (11.1+2.0
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Holter ECG findings in the two groups
FAs
(n5 62)
Controls
(n 5 62)
P-value
Heart rate, mean, b.p.m. 66+9 70+8 0.004
Heart rate, minimal, b.p.m. 49+8 51+6 0.05
Heart rate, maximal, b.p.m. 124+26 124+17 0.97
Heart rate ,50 b.p.m.
during the day, n (%)
20 (32) 6 (10) 0.004
Heart rate ,40 b.p.m.
Ever, n (%) 6 (10) 1 (2) 0.11
During the day, n (%) 2 (3) 0 0.49
During the night, n (%) 6 (10) 1 (2) 0.11
Maximal RR interval, ms
(mean)
1761+702 1499+223 0.007
median (range) 1565 (1031–
5300)
1500 (1100–
2160)
Maximal RR interval.2.5 s 4 (6%) 0 0.12
FAs, former athletes.
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Table 2 Comparison of findings of resting ECG
FAs
(n5 62)
Controls
(n 5 62)
P-value
Heart rate, b.p.m. 58+10 63+9 0.01
PR interval, ms 186+37 177+24 0.14
QRS duration, ms 102+20 95+13 0.027
Corrected QT interval, ms 416+27 404+18 0.004
Left bundle branch block 0 0
Left anterior hemiblock, n (%) 3 (5) 3 (5) 1.0
Left posterior hemiblock, n (%) 0 1 (2) 1.0
RBBB complete, n (%) 0 3 (5) 0.24
RBBB incomplete, n (%) 2 (3) 1 (2) 1.0
AV block, n (%) 8 (13) 9 (15) 1.0
First degree 7 (11) 8 (13)
Second degree 0 1 (2)
Third degree, n (%) 1 (2) 0
Atrial flutter or fibrillation, n (%) 6 (10) 0 0.028
RBBB, right bundle branch block; AV, atrioventricular; FAs, former athletes.
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Table 4 Supraventricular arrhythmias
FAs
(n5 62)
Controls
(n 5 62)
P-value
Atrial premature complexes per 24 h
Median (range) 18 (0–2616) 17 (1–6135) 0.35
Atrial premature complexes
None ,1/h, n (%) 35 (56) 39 (63)
Rare, n (%) 23 (37) 19 (31)
Occasional, n (%) 3 (5) 2 (3)
Frequent, n (%) 1 (2) 2 (3)
Number of subjects with
SVT, n (%)
21 (34) 19 (31) 0.82
Number of runs of SVT
Mean 0.7+1.3 0.7+1.4 0.88
Median (range) 0 (0–7) 0 (0–7)
FAs, former athletes; SVT, supraventricular tachycardia.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Comparison of ventricular arrhythmias
FAs
(n5 62)
Controls
(n5 62)
P-value
Number of subjects with
VPCs, n (%)
28 (45) 22 (35) 0.12
Number of VPCs per 24 h
Total 337+1054 390+1211 0.59a
Median (range) 32 (0–7780) 67 (0–7792)
None/rare VPCs 49 48
Occasional VPCs 10 10
Frequent VPCs 3 4
Couplets of VPC
Mean 12+72 8+33 0.70*
Median (range) 0 (0–569) 0 (0–222)
Subjects with VT 9 (15%) 2 (3%) 0.05
FAs, former athletes VPCs; ventricular premature complexes; VT, ventricular
tachycardia.
aMann–Whitney test.
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in FAs vs. 11.2+2.0 in controls, P ¼ 0.79). The left ventricular
muscle mass index tended to be larger in FAs with 110+32 g/m2
body surface area (median. 108; range, 51–213) vs. 101+17 g/m2
(median, 96; range, 61–142) in controls (P ¼ 0.07). The LVEDD
was 51+4 mm in FAs vs. 49+ 5 mm in controls (P ¼ 0.04).
Left and right atrial size indexed for body surface area was larger
in FAs than in controls: left atrial volume index was 30+13 ml/
m2 body surface area in 57 FAs in sinus rhythm (median, 27;
range, 12–73) vs. 24+8 ml (median, 32; range, 8–68) in 62 con-
trols (P ¼ 0.02); right atrial volume index was 29+ 12 in 57 FAs in
sinus rhythm (median, 26; range, 10–60) vs. 23+8 in 62 controls
(median, 22; range, 10–44) (P ¼ 0.002).
Survival curve
Cumulative survival of 119 FA participating in the Tour de Suisse
from 1955 to 1975 is shown in Figure 1 as a Kaplan–Meier survival
curve. Survival of FAs was similar to a matched Swiss male
population.
Discussion
Our study suggests that extreme high endurance training might not
only have physiological consequences such as signs of SND with
bradycardia of ,40 b.p.m., atrial flutter, prior pacemaker insertion
for bradyarrhythmias and/or maximal RR interval of .2.5 s were
more common in FAs (18%) than in controls (2%, P ¼ 0.004).
Also, in the FAs, the incidence of atrial flutter or fibrillation was
higher and QRS duration and corrected QTc interval were
longer at long-term follow-up.
Atrioventricular block and sinus
node disease
Sinus bradycardia and atrioventricular conduction abnormalities
including first and second-degree (Wenckebach) AV block rep-
resent part of the spectrum of arrhythmias in active endurance
athletes.6 Some of the changes are induced by increased parasym-
pathetic and reduced sympathetic activity.18 And also non-
autonomic factors contribute to change in AV conduction. It was
shown that sinus cycle length and sinus node recovery time
were longer in endurance athletes after atropine and after propra-
nolol, also the Wenckebach cycle and anterograde refractory
period of the AV node.18 In our FAs, there was no significant differ-
ence in PR intervals and no increase in the occurrence of AV block.
This underlines that changes in AV conduction are mostly related
to higher parasympathetic activity owing to their association with
active training.19 However, signs for intrinsic SND are present in
the FA. Whereas in the active athlete, sinus bradycardia without
symptoms is common and does not usually warrant further
testing or treatment,9 this is different in the elderly former high-
endurance athlete. Clearly, SND seems to be a significant side-
effect of high-endurance training performed during many years.
Especially, its association with atrial flutter and atrial fibrillation
and the need for pacemaker implantation suggest that it might
also affect morbidity in these people. Our study is the largest on
this topic with case-matched controls. The natural history study
in SND depends on the underlying disease. However, there are
a few data in the literature that raise concern on its impact on sur-
vival.20 In a study with 35 untreated patients with SND aged
45 years, during a follow-up of 17+15 months, 57% of patients
had a cardiovascular event including syncope, heart failure, and
tachyarrythmias.20
Atrial flutter or atrial fibrillation
Our former cyclists had significantly more atrial fibrillation/atrial
flutter (P ¼ 0.028). It has been described that vigorous long-term
exercise is associated with atrial fibrillation in healthy middle
aged men.13,21 However, only few data are available. In one of
these studies, the first attack of ‘lone’ atrial fibrillation in top
veteran orienteers was at a mean age of 52 years (range 34–68
years) after an average training history of 36 years; there were
also three episodes of atrial flutter.13 Enhanced vagal tone and/
or changes of the athlete’s heart including enlarged atria and left
ventricular hypertrophy may predispose the hearts to these
arrhythmias.13 Among patients with the so-called lone atrial
fibrillation, the percentage of sportsmen is higher with 31–63 vs.
14–15% in the general population in several studies.22,23 Most of
these arrhythmias seem to be vagal (in 57%) occurring more
commonly during sleep or after meals compared with 18% in
Figure 1 Survival curve of former athletes participating in the Tour de Suisse compared with a male age- and calendar time-matched Swiss
reference population. The dotted lines represent a 95% pointwise confidence interval for the Kaplan–Meier estimate
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the non-sport patients.22 Vagally induced atrial fibrillation was seen
in 33–37% of male endurance athletes during a 9 year follow-up of
atrial fibrillation.24 In that study, older athletes presented with
vagally induced atrial fibrillation more often than younger athletes.
In our study, FA with a very high number of previous bicycle years
had a higher left ventricular muscle mass, larger atria, and a signifi-
cant higher occurrence of atrial fibrillation or flutter correlating
with previous bicycle years indicating that there might be
a threshold above which irreversible cardiac changes occur as
another cause for atrial fibrillation or flutter. An association of a
lifetime practice of .1500 h of sport was also associated with
lone atrial fibrillation in another study, so there seems to be a
threshold.23
In a study among 30 well-trained athletes with paroxysmal atrial
fibrillation, permanent atrial fibrillation emerged in 17% of athletes,
10% of the 30 athletes had also atrial flutter.24 In our athletes, atrial
flutter was more common (in four FAs) than atrial fibrillation
(in two FAs). In Hoogsteen’s study, it has been suggested that
persistent atrial fibrillation developed in only a minority of male
endurance athletes.24
Significance of QRS and QTc
prolongation
In the FAs, QRS duration and corrected QTc were slightly longer.
This might be because of residual fibrosis of the myocardium,
which is also reflected in the slightly higher left ventricular
muscle that can be an explanation for the tendency of ventricular
tachycardias to occur more often in FAs than in controls. So far,
there are no autopsy data on the hearts of previous high-
endurance athletes, which quantify fibrosis and other residual
damage in these subjects. It has been shown in individuals with
left ventricular hypertrophy secondary to essential hypertension
that both QTc and QRS duration can correlate with left ventricular
muscle mass25,26 and may be predictive of ventricular arrhythmias
and cardiovascular mortality as well.25,27
Ventricular arrhythmias
Frequent and/or complex ventricular arrhythmias occur frequently
in trained athletes with physiological left ventricular hypertro-
phy.11,28 These arrhythmias are very sensitive to deconditioning
in athletes with and without structural heart disease: an impressive
80% decrease (from 10 611+10 078 to 2165+4877) has been
described as well as a 90% decrease in the occurrence of
non-sustained ventricular tachycardias with deconditioning.28
However, ventricular arrhythmias in active endurance athletes do
not necessarily represent a benign finding and can be because of
changes in right ventricular structure or right ventricular
arrhythmic involvement.29 In our study, FAs tended to have only
slightly more ventricular tachycardias than the controls. From
this small difference, we cannot draw any definite conclusions
and still assume that most ventricular arrhythmias are indeed
reversible in athletes. It should be considered that the control
group had significantly more smokers than the FA group, and it
was shown by the Trial-II investigators that especially current
smoking increases the incidence of fast ventricular tachycardia
or ventricular fibrillation and may also be associated with
supraventricular tachycardias.30 Therefore, comparing FAs with a
control group with fewer smokers might increase the relevance
of a higher incidence of ventricular tachycardias in FA even more.
We do not have data on the impact of ventricular arrhythmias
on survival in this group of FAs. The reported incidence of
sudden death in athletes is low (1:200 000 to 1:300 000).31
Sudden death in the athletes is not usually because of acquired
arrhythmias as a result of endurance training, but because of
underlying congenital heart disease, coronary artery anomalies,
and other rare causes such as cardiomyopathies or myocarditis,
etc.31,32 Still, the more frequent occurrence of ventricular
tachycardias in FAs reinforces the need to investigate always the
cause of death in cyclists. Besides, cardiac screening during and
after high-level athletic participation should be performed in all
former endurance athletes including cyclists, orienteers, rowers,
marathon runners, triathletes, etc. with a resting ECG and—if
this is abnormal and/or if there are cardiac symptoms such as
palpitations, dizziness or syncope—by further examination by
echocardiography, and Holter ECG.
Limitations
Cause of death in six of 24 deceased athletes is not known to us.
Besides, 11 athletes could not be traced. This might have resulted
in positive selection bias with underestimation of cardiac morbidity
because of rhythm disturbances with stroke or sudden cardiac
death. However, sudden cardiac death was not reported in 18 of
24 dead former cyclists in whom cause of death is known.
Another limitation is that 32% (29 of 91) of the available FAs
were not willing to participate. The impact of this selection bias
is difficult to judge.
The impact of illicit drugs including anabolic steroids could be a
contributing factor to the arrhythmias. The information of the
exact intake and dosage of these drugs is hard to get. The percen-
tage of FAs in our study admitting the use of amphetamines or
other drugs was amazingly high. During the 1950s and 1960s,
amphetamines were not illegal, yet. However, cardiotoxic drugs
do not typically cause SND, but if anything tachyarrhythmias.3
Former FAs were still doing slightly more endurance training
than the controls; however, the percentage of persons performing
.4 h of cardiovascular training was similar.
This study is not aimed at comparing risks and benefits of per-
forming high-endurance training at any level or comparing different
levels. We chose not a sedentary control group to make the diffe-
rence not too striking but a group of individuals performing a mod-
erate amount of physical activity.33
Currently, we cannot make any recommendations how to
identify endurance athletes who will develop SND in the long-
term follow-up. Perhaps, in the future, we will recognize that
in endurance athletes with a resting heart rate of ,40 b.p.m. at
day time, the likelihood of later SND is high and that these
athletes might be encouraged to reduce or change their training
program.
Conclusions
It is doubtful that long-term endurance level at a very high level
induces only physiological and fully reversible changes of the
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heart. The elderly athlete may not be as healthy as believed: among
FAs, SND occurred significantly more often compared with age-
matched controls. Also there is a trend towards more frequent
atrial fibrillation/atrial flutter and ventricular tachycardias in FAs.
Further studies have to evaluate the impact on how to advise
the public on clinical follow-up and management of arrhythmias
in former competitive endurance athletes.
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An unusual cause of dyspnoea in an 83-year-old woman
Karin K.M. Chia*, Kanthale Kailanathan, and Michael R. Ward
Department of Cardiology, Royal North Shore Hospital, Pacific Hwy, St Leonards, NSW 2065, Australia
* Corresponding author. Tel: þ61 2 99268687, Fax: þ61 2 99067807. Email: km_chia@yahoo.com
An 83-year-old woman was referred for assessment of rapidly
worsening dyspnoea, limiting mobility to 10 yards. She had a history of
multiple potential sources of her dyspnoea: coronary artery disease
(previous stenting of the right coronary artery, a chronic total occlusion
of the mid left anterior descending artery, and 50% stenosis in the circum-
flex with normal left ventricular function), chronic obstructive airways
disease requiring inhaled bronchodilators and steroids, and chronic
renal impairment with a mild anaemia. She had also been noted to
have a stable aneurysm of the ascending aorta (4.5 cm in diameter) at
last angiography 2 years before.
Examination at 458 revealed central cyanosis with oxygen saturation of
88% on room air but normal jugular venous pressure and clear lung fields
to auscultation. On lying flat, the oxygen saturation improved to 92%.
Ventilation perfusion lung scan indicated a low probability for pulmonary
emboli. Chest X-ray showed widening of the superior mediastinum with
the enlargement of the cardiac silhouette. Computed tomography (CT)
aortogram showed an ascending aortic aneurysm with a maximum dia-
meter of 6.8 cm (Panel A), substantially larger than the last measurement
2 years before. Transthoracic echocardiography showed a markedly
dilated ascending aorta impinging on the right atrial free wall resulting
in a functional tricuspid stenosis (mean gradient 5 mmHg), with contrast
bubble study demonstrating a right-to-left shunt through a patent
foramen ovale (PFO) (Panels B and C). Hyperoxic pulmonary function
testing showed a shunt of 24%. The patient declined aortic surgery and
was discharged on home oxygen, but agreed to consider palliative per-
cutaneous PFO closure. However, 2 days later, she presented with
chest pain. Repeat CT now showed dissection of the enlarging ascending
aortic root aneurysm. The patient requested active measures be withdrawn and she died a few hours later.
This case illustrates an unusual mode of presentation for an ascending aortic aneurysm: marked hypoxia with cyanosis due to right-to-left intracardiac
shunting resulting from right atrial compression. There were multiple other possible causes of dyspnoea including coronary ischaemia, left ventricular
systolic or diastolic dysfunction, worsening of airflow limitation, anaemia, or fluid overload from chronic renal impairment. However, hypoxia with clear
lung fields on examination and on chest X-ray suggested intracardiac right-to-left shunting as the cause.
Intracardiac right-to-left shunting can be interventricular but usually occurs across the atrial septum through an atrial septal defect or more com-
monly through a PFO and only when the right atrial pressure exceeds the left atrial pressure. Isolated elevation of the right atrial pressure is usually due
to pulmonary hypertension but may also occur with obstruction to right atrial outflow (due to right atrial myxoma, tricuspid stenosis, or localized right
ventricular dysfunction) and extrinsic compression of the right atrium (due to tumour, localized pleural or pericardial effusion, or, as in this case, due to
aortic root enlargement).
Platypnoea-orthodeoxia syndrome (where dyspnoea and cyanosis are characteristically worse in the upright posture and improved by lying supine) is
a rare condition usually where there is distortion of the interatrial septum, opening a PFO, which is exacerbated by erect posture. Distortion of the
interatrial septum may result from right pneumonectomy/lobectomy or abnormal aortic root anatomy. Enlargement of the ascending aorta rotates the
heart anti-clockwise and may result in anterior displacement of the superior limbus of the foramen ovale into the right atrial cavity, causing a PFO to be
held open while compression of the right atrium raises pressure, promoting right-to-left shunting. The effects of gravity in the erect position cause
further anterior and inferior displacement of the aortic root increasing PFO aperture size and right atrial compression resulting in increased shunting
and worsening of hypoxia.
Panel A Computed tomography scan of the thorax in the sagittal plane demonstrating the ascending aortic aneurysm (arrow) with a maximum
diameter of 6.8 cm.
Panel B Transthoracic echocardiogram from the subcostal view before bubble contrast injection showing the atrial pacing lead (arrow) in the right
atrium, but no contrast in either atrium.
Panel C Similar view on transthoracic echo after bubble contrast injection showing right-to-left shunting across a patent foramen ovale (white
arrow), as a result of the right atrial compression, with contrast filling the right atrium (RA) but also seen in the left atrium (LA).
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